Search Result

Results for "

DHODH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dihydroorotate Dehydrogenase (58) Apoptosis (1) Autophagy (3) Bacterial (2) Dengue virus (1) DNA/RNA Synthesis (31) Endogenous Metabolite (6) Ferroptosis (1) Flavivirus (1) Fungal (1) FXR (2) Influenza Virus (2) Interleukin Related (2) Isotope-Labeled Compounds (2) MDM-2/p53 (3) Nucleoside Antimetabolite/Analog (4) Parasite (9) Prostaglandin Receptor (1) Reactive Oxygen Species (1) ROR (5) SARS-CoV (3) Sirtuin (3) Small Interfering RNA (siRNA) (3) VEGFR (1) Virus Protease (2)
By Research Areas:	Cancer (32) Infection (23) Inflammation/Immunology (20) Metabolic Disease (4)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Dihydroorotate Dehydrogenase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139189

DHODH-IN-16	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.396 nM for human DHODH .

HY-135282

DHODH-IN-1	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC₅₀ of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway .

HY-135675

DHODH-IN-11	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pK_a of 5.03 .

HY-163158

DHODH-IN-24	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-24 (compound 16) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 91 nM .

HY-135677

DHODH-IN-13	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 4.3 μM for rat liver DHODH. DHODH-IN-13 can be used for rheumatoid arthritis .

HY-135676

DHODH-IN-12	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pK_a of 5.07 .

HY-135678

DHODH-IN-14	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis .

HY-135679

DHODH-IN-15	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-15 (Compound 7b) is a hydroxyfurazan analog of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis .

HY-135666

DHODH-IN-8	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-8 (Compound 27) is an inhibitor of human and **Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC₅₀s of 0.13 μM and 47.4 μM, and K_i*s of 0.016 μM and 5.6 μM, respectively. DHODH*-IN-8 has antimalarial activity .

HY-144169

DHODH-IN-19	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology Cancer
DHODH-IN-19 is a potent inhibitor of *DHODH. DHODH* is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-19 inhibits tumor growth. DHODH-IN-19 has the potential for the research of cancer and inflammation disease (extracted from patent WO2021238881A1, compound 1) .

HY-144371

DHODH-IN-20	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology Cancer
DHODH-IN-20 (Compound 133) is a potent inhibitor of *DHODH. DHODH* is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-20 inhibits tumor growth. DHODH-IN-20 has the potential for the research of acute myelogenous leukemia .

HY-149030

DHODH-IN-21	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML) .

HY-163328

DHODH-IN-25	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 5.4 nM for human *DHODH. DHODH*-IN-25 can be used for the study of acute myeloid leukemia (AML) .

HY-139889

DHODH-IN-18	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-18 is a human *DHODH* inhibitor (IC₅₀ = 0.2 nM).

HY-135618

DHODH-IN-3	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-3 (compound 3) is a potent inhibitor of Human Dihydroorotate Dehydrogenases (HsDHODH) with an IC₅₀ value of 261 nM. DHODH-IN-3 binds to the the ubiquinone binding cavities in DHODH with a K_i ^app of 32 nM. DHODH-IN-3 has the potential for malaria treatment .

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

HY-153112

DHODH-IN-23	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-23 (Compound A) is an orally active *DHODH* inhibitor that can be used for the research of cancer .

HY-128068

DHODH-IN-17	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-17, a 2-anilino nicotinic acid, is a human *DHODH* inhibitor (IC₅₀=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML) .

HY-158023

DHODH-IN-26	Dihydroorotate Dehydrogenase Reactive Oxygen Species Ferroptosis	Cancer
DHODH-IN-26 (compound B2) is a mitochondria-targeting *DHODH* inhibitor. DHODH-IN-26 shows anticancer activity, triggers the formation of reactive oxygen species (ROS), promots mitochondrial lipid peroxidation, and induces ferroptosis .

HY-135619

DHODH-IN-4	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection Inflammation/Immunology
DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor, with IC₅₀ values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity .

HY-RS03734

DHODH Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DHODH Human Pre-designed siRNA Set A contains three designed siRNAs for DHODH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DHODH Human Pre-designed siRNA Set A DHODH Human Pre-designed siRNA Set A

HY-RS03735

Dhodh Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dhodh Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dhodh gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dhodh Mouse Pre-designed siRNA Set A Dhodh Mouse Pre-designed siRNA Set A

HY-RS03736

Dhodh Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dhodh Rat Pre-designed siRNA Set A contains three designed siRNAs for Dhodh gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dhodh Rat Pre-designed siRNA Set A Dhodh Rat Pre-designed siRNA Set A

HY-142843

*RORγt/DHODH-IN-1*	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC₅₀s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity .

HY-142834

*RORγt/DHODH-IN-2*	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-169220S

*RORγ/DHODH-IN-1*	ROR Dihydroorotate Dehydrogenase DNA/RNA Synthesis Isotope-Labeled Compounds	Infection
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and *DHODH* inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .

HY-142847

*RORγt/DHODH-IN-3*	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-3 (compound (S)-14d) is a dual RORγt/DHODH inhibitor, with IC₅₀s of 0.098 μM and 0.432 μM, respectively. RORγt/DHODH-IN-3 exhibits remarkable in vivo anti-inflammatory activity .

HY-169222S

*RORγ/DHODH-IN-2*	Dihydroorotate Dehydrogenase ROR SARS-CoV	Infection
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .

HY-132170

DSM502	Dihydroorotate Dehydrogenase Parasite	Infection
DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs .

HY-132171A

DSM705 hydrochloride	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC₅₀=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs .

HY-132171

DSM705	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. DSM705 is a potent antimalarial compound .

HY-135667

hDHODH-IN-7	DNA/RNA Synthesis Influenza Virus Dihydroorotate Dehydrogenase	Infection
DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a human dihydroorotate dehydrogenase inhibitor. DHODH-IN-9 has antiviral effect with a pMIC₅₀ of 7.4 .

HY-137463

AG-636	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 17 nM. AG-636 has strong anticancer effects .

HY-132174

CHIKV-IN-2	Flavivirus Dengue virus Dihydroorotate Dehydrogenase	Infection
CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC₉₀=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools .

HY-N6961

Lapachol 2 Publications Verification	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection Inflammation/Immunology Cancer
Lapachol, a natural naphthoquinone, is an orally active, potent *DHODH* inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-N6961R

Lapachol (Standard)	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection Inflammation/Immunology Cancer
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-129239

Farudodstat 2 Publications Verification ASLAN003	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Apoptosis	Cancer
Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC₅₀ of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice .

HY-135664

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia .

HY-128787

hDHODH-IN-4	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Influenza Virus	Infection
hDHODH-IN-4 is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor, with a pIC₅₀ of 7.8 for human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication, with a pMIC₅₀ of 8.8 .

HY-108325

Brequinar Maximum Cited Publications 17 Publications Verification DUP785; NSC 368390	Dihydroorotate Dehydrogenase SARS-CoV Virus Protease DNA/RNA Synthesis	Infection Inflammation/Immunology Cancer
Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity.

HY-139825

Indoluidin E	Dihydroorotate Dehydrogenase	Cancer
Indoluidin E selectively inhibits *DHODH* and suppresses cancer cell growth.

HY-112645

BAY-2402234 5+ Cited Publications	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
BAY-2402234 is a selective dihydroorotate dehydrogenase *(DHODH)* inhibitor for the treatment of myeloid malignancies.

HY-146317

P1788	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology Cancer
P1788 is a dihydroorotate dehydrogenase (DHODH) inhibitor. P1788 induces DNA damage .

HY-B0083

Leflunomide 5+ Cited Publications HWA486; RS-34821; SU101	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-149877

hDHODH-IN-12	DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-12 is a potent *DHODH* inhibitor with an IC₅₀ value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer .

HY-108325S

Brequinar-d3 DUP785-d₃; NSC 368390-d₃	Isotope-Labeled Compounds Virus Protease Dihydroorotate Dehydrogenase DNA/RNA Synthesis SARS-CoV	Infection Inflammation/Immunology Cancer
Brequinar-d₃ (DUP785-d₃) is deuterium labeled Brequinar. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity .

HY-N7961

(E/Z)-Ginkgolic acid C17:2	Dihydroorotate Dehydrogenase	Others
(E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human dihydroorotate dehydrogenase (DHODH) tightly .

HY-B0083R

Leflunomide (Standard)	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-120924

BRD9185	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection
BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC₅₀ of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model .

HY-148395

UCK2 Inhibitor-2	Dihydroorotate Dehydrogenase	Cancer
UCK2 Inhibitor-2 is a non-competitive uridine-cytidine kinase 2 (UCK2) inhibitor with an IC₅₀ value of 3.8 µM. UCK2 Inhibitor-2 can suppress uridine salvage in cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6961

Lapachol 2 Publications Verification	Infection Quinones Structural Classification Classification of Application Fields Tabebuia avellanedae Bignoniaceae Plants Naphthalene Quinones Inflammation/Immunology Disease Research Fields	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite
Lapachol, a natural naphthoquinone, is an orally active, potent *DHODH* inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-B0083

Leflunomide Maximum Cited Publications 8 Publications Verification HWA486; RS-34821; SU101	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-N7961

(E/Z)-Ginkgolic acid C17:2	Monophenols Classification of Application Fields Ginkgoaceae Ketones, Aldehydes, Acids Source classification Other Diseases Phenols Plants Disease Research Fields Ginkgo biloba	Dihydroorotate Dehydrogenase
(E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human dihydroorotate dehydrogenase (DHODH) tightly .

HY-N0157

Orotic acid 2 Publications Verification 6-Carboxyuracil; Vitamin B13	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-N0157A

Orotic acid zinc 2 Publications Verification 6-Carboxyuracil zinc; Vitamin B13 zinc	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

HY-N6961R

Lapachol (Standard)	Quinones Structural Classification Tabebuia avellanedae Bignoniaceae Plants Naphthalene Quinones	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-B0083R

Leflunomide (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-N0157R

Orotic acid (Standard) 6-Carboxyuracil (Standard); Vitamin B13 (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

Cat. No.	Compare	Product Name	Species	Source

HY-P78957

	Dihydroorotate Dehydrogenase Protein, Human (His) Dihydroorotate dehydrogenase (quinone), mitochondrial; DHODH; DHOdehase; Dihydroorotate oxidase; Dihydroorotate Dehydrogenase	Human	E. coli
	Dihydroorotate dehydrogenase is a key enzyme that utilizes quinones as electron acceptors to catalyze the key conversion of dihydroorotate to orotic acid. This enzyme activity is essential for the de novo biosynthesis of UMP (uridine monophosphate), an essential component of nucleotide metabolism. Dihydroorotate Dehydrogenase Protein, Human (His) is the recombinant human-derived Dihydroorotate Dehydrogenase protein, expressed by E. coli , with N-His labeled tag. The total length of Dihydroorotate Dehydrogenase Protein, Human (His) is 365 a.a., with molecular weight of ~41 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0157S1

Orotic acid-13C,15N2 monohydrate

Orotic acid- ¹³C, ¹⁵N₂ (monohydrate) is the ¹³C and ¹⁵N labeled Orotic acid[1]. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[2][3][4].

HY-169220S

*RORγ/DHODH-IN-1*
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and *DHODH* inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .

HY-169222S

*RORγ/DHODH-IN-2*
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .

HY-108325S

Brequinar-d3
Brequinar-d₃ (DUP785-d₃) is deuterium labeled Brequinar. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity .

HY-B0083S

Leflunomide-d4
Leflunomide-d₄ (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks